Bbot

Bbot company information, Employees & Contact Information

Explore related pages

Related company profiles:

BBOT (BridgeBio Oncology Therapeutics) is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BBOT completed a $200M private financing with external investors in 2024 with the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.

Company Details

Employees
69
Address
1 Corporate Drive, South San Francisco,ca 94080,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, CA
Looking for a particular Bbot employee's phone or email?

Bbot Questions

News

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire

BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines Business Wire

BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRAS - Business Wire

BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRAS Business Wire

BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive

BridgeBio oncology spinout to go public in blank-check merger BioPharma Dive

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) - GlobeNewswire

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) GlobeNewswire

BridgeBio Oncology Therapeutics and Helix Acquisition Corp. II To Merge - citybiz

BridgeBio Oncology Therapeutics and Helix Acquisition Corp. II To Merge citybiz

BridgeBio Oncology and Helix enter definitive merger agreement - Pharmaceutical Technology

BridgeBio Oncology and Helix enter definitive merger agreement Pharmaceutical Technology

BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs - MedCity News

BridgeBio Oncology to Go Public in SPAC Deal Bringing $450M+ for Trio of Cancer Drugs MedCity News

BridgeBio’s oncology spinout must stand out from the crowd | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

BridgeBio’s oncology spinout must stand out from the crowd | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors Business Wire

BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal - BioSpace

BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal BioSpace

BridgeBio Oncology Therapeutics launches with $200m funding - Pharmaceutical Technology

BridgeBio Oncology Therapeutics launches with $200m funding Pharmaceutical Technology

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - Business Wire

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director Business Wire

BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Business Wire

BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors Business Wire

BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer - Business Wire

BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer Business Wire

Top Bbot Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant